Taranabant cuts the fat: new hope for cannabinoid-based obesity therapies?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 18177717.
- Also identified by DOI 10.1016/j.cmet.2007.12.006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Endocannabinoid/cannabinoid receptor signaling acts centrally and peripherally to govern appetite and energy balance. While system stimulation promotes eating and energy storage, receptor blockade can reduce food intake and facilitate weight loss. In this issue of Cell Metabolism, Addy et al. (2008) test the therapeutic antiobesity potential of taranabant, a cannabinoid 1 receptor inverse agonist.
Medical subject headings
- Amides
- Cannabinoids
- Obesity
- Pyridines